Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ILD, Healthy, Pneumonia.
- Who it may be relevant to
- Registry conditions: Interstitial Lung Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.
Detailed description
The proposed biospecimen repository would be derived from patients diagnosed with ILD. This is to include 500 patients in the repository, with each patient contributing one blood sample. Patients with pneumonia and healthy patients will also be recruited as a control group.
Interventions
- Other ILD
100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis - Other Healthy
100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants. - Other Pneumonia
100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
Primary outcome measures
- Future Disease Management [Time frame: 1 visit]
Eligibility criteria
Inclusion criteria
- Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia
- Patients willing to provide written informed consent
Exclusion criteria
- Unwillingness/unable to give blood samples
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Other
Study locations
United States · 1 center
- Mayo Clinic — Rochester
Identifiers
NCT: NCT03478826 · 17-008088